Cargando…

Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study

BACKGROUND: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Fei, Zhang, Hui, Lv, Qing, Sato, Kaori D., Qu, Yan, Huan, Shitong, Cheng, Jun, Zhao, Fei, Wang, Lixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720996/
https://www.ncbi.nlm.nih.gov/pubmed/26792535
http://dx.doi.org/10.1186/s40249-016-0098-9
_version_ 1782411156531445760
author Huang, Fei
Zhang, Hui
Lv, Qing
Sato, Kaori D.
Qu, Yan
Huan, Shitong
Cheng, Jun
Zhao, Fei
Wang, Lixia
author_facet Huang, Fei
Zhang, Hui
Lv, Qing
Sato, Kaori D.
Qu, Yan
Huan, Shitong
Cheng, Jun
Zhao, Fei
Wang, Lixia
author_sort Huang, Fei
collection PubMed
description BACKGROUND: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB drug use for newly diagnosed pulmonary TB inpatients treated in prefecture- and county-level designated hospitals. METHODS: Three prefecture-level hospitals and nine county-level hospitals were selected for the study. All newly diagnosed pulmonary TB inpatient medical records from 2012 were reviewed and doubly examined by two national senior physicians. The rational use of anti-TB drugs was evaluated based on criteria in line with WHO’s guideline. RESULTS: Of the 2,060 total treatment regimens for TB, 53.1 % were found to be rational (1093/2060). The percentages in prefecture-level and county-level hospitals were 50.3 % (761/1513) and 60.7 % (332/547), respectively. The difference between the two levels of hospitals was statistically significant (Chi-square value = 17.44, P < 0.01). The percentages of rational treatment regimens for first-time hospitalizations and for two or more hospitalizations were 59.5 % (983/1653) and 27.0 % (110/407), respectively, with a statistically significant difference (Chi-square value = 138.00, P < 0.01). The overall use of second-line drugs (SLD) was 54.9 % (1131/2060). The percentages for prefecture-level and county-level hospitals were 50.6 % (766/1513) and 66.7 % (365/547), respectively. A statistically significant difference was found (Chi-square value = 42.06, P < 0.01). The use of SLD for inpatients hospitalized once and inpatients hospitalized twice or more was 58.4 % (966/1653) and 40.5 % (165/407), respectively, with a statistically significant difference (Chi-square value = 42.26, P < 0.01). CONCLUSIONS: Half of inpatients might be treated with irrational regimens, and the use of SLD was more appropriately dispensed in city-level hospitals than in county-level hospitals. Trainings and guidelines for health personnel, supervision led by health authorities and increased investment to designated hospitals may help to improve the rational use of anti-TB drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-016-0098-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4720996
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47209962016-01-22 Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study Huang, Fei Zhang, Hui Lv, Qing Sato, Kaori D. Qu, Yan Huan, Shitong Cheng, Jun Zhao, Fei Wang, Lixia Infect Dis Poverty Research Article BACKGROUND: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB drug use for newly diagnosed pulmonary TB inpatients treated in prefecture- and county-level designated hospitals. METHODS: Three prefecture-level hospitals and nine county-level hospitals were selected for the study. All newly diagnosed pulmonary TB inpatient medical records from 2012 were reviewed and doubly examined by two national senior physicians. The rational use of anti-TB drugs was evaluated based on criteria in line with WHO’s guideline. RESULTS: Of the 2,060 total treatment regimens for TB, 53.1 % were found to be rational (1093/2060). The percentages in prefecture-level and county-level hospitals were 50.3 % (761/1513) and 60.7 % (332/547), respectively. The difference between the two levels of hospitals was statistically significant (Chi-square value = 17.44, P < 0.01). The percentages of rational treatment regimens for first-time hospitalizations and for two or more hospitalizations were 59.5 % (983/1653) and 27.0 % (110/407), respectively, with a statistically significant difference (Chi-square value = 138.00, P < 0.01). The overall use of second-line drugs (SLD) was 54.9 % (1131/2060). The percentages for prefecture-level and county-level hospitals were 50.6 % (766/1513) and 66.7 % (365/547), respectively. A statistically significant difference was found (Chi-square value = 42.06, P < 0.01). The use of SLD for inpatients hospitalized once and inpatients hospitalized twice or more was 58.4 % (966/1653) and 40.5 % (165/407), respectively, with a statistically significant difference (Chi-square value = 42.26, P < 0.01). CONCLUSIONS: Half of inpatients might be treated with irrational regimens, and the use of SLD was more appropriately dispensed in city-level hospitals than in county-level hospitals. Trainings and guidelines for health personnel, supervision led by health authorities and increased investment to designated hospitals may help to improve the rational use of anti-TB drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-016-0098-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-21 /pmc/articles/PMC4720996/ /pubmed/26792535 http://dx.doi.org/10.1186/s40249-016-0098-9 Text en © Huang et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Huang, Fei
Zhang, Hui
Lv, Qing
Sato, Kaori D.
Qu, Yan
Huan, Shitong
Cheng, Jun
Zhao, Fei
Wang, Lixia
Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
title Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
title_full Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
title_fullStr Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
title_full_unstemmed Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
title_short Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
title_sort use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in china: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720996/
https://www.ncbi.nlm.nih.gov/pubmed/26792535
http://dx.doi.org/10.1186/s40249-016-0098-9
work_keys_str_mv AT huangfei useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT zhanghui useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT lvqing useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT satokaorid useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT quyan useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT huanshitong useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT chengjun useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT zhaofei useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy
AT wanglixia useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy